Debut Plus

116.91

+0.37 +0.32%

As of 09 Sept 2026 · delayed

NSE Listed

LT-ASM · ASM 1 · ST-ASM · ASM 1
What does LT-ASM · ASM 1 · ST-ASM · ASM 1 mean?
BSE · Long Term Additional Surveillance Measure (ASM 1)LT-ASM is the joint SEBI/exchange framework for SUSTAINED abnormal price moves (contrast ST-ASM's 5–15-day spikes). Entry is beta-adjusted price variation versus the Nifty (e.g. 3-month high-low above 150% plus the stock's β × index move) along with client-concentration checks. Stages I–IV escalate from a 5% price band through 100% margin to Trade-for-Trade with an additional surveillance deposit. Practical meaning: the exchange still considers the price action abnormal — tighter bands and elevated margins continue even if another measure (like ESM) has lifted. A stock can sit under LT-ASM on both exchanges via either exchange's shortlisting; it is a preventive cost-of-speculation measure, not an adverse finding against the company.Criteria: High 3-month / 12-month high-low price variation, close-to-close price variation, client concentration, number of price-band hits, market-wide position limit and P/E — applied in graded Stages I–IV with escalating margin and price-band curbs.Exchange notice · 2026-08-18
NSE · Long Term Additional Surveillance Measure (ASM 1)LT-ASM is the joint SEBI/exchange framework for SUSTAINED abnormal price moves (contrast ST-ASM's 5–15-day spikes). Entry is beta-adjusted price variation versus the Nifty (e.g. 3-month high-low above 150% plus the stock's β × index move) along with client-concentration checks. Stages I–IV escalate from a 5% price band through 100% margin to Trade-for-Trade with an additional surveillance deposit. Practical meaning: the exchange still considers the price action abnormal — tighter bands and elevated margins continue even if another measure (like ESM) has lifted. A stock can sit under LT-ASM on both exchanges via either exchange's shortlisting; it is a preventive cost-of-speculation measure, not an adverse finding against the company.Criteria: High 3-month / 12-month high-low price variation, close-to-close price variation, client concentration, number of price-band hits, market-wide position limit and P/E — applied in graded Stages I–IV with escalating margin and price-band curbs.Exchange notice · 2026-08-19
BSE · Short Term Additional Surveillance Measure (ASM 1)ST-ASM catches short bursts: a beta-adjusted close-to-close move beyond ±25% in 5 trading days (or ±40% in 15) combined with concentrated trading — or a 75%+ monthly range with fewer than 100–200 unique traders. Practical meaning: margins jump to 50–100% for a few weeks to cool a spike; it either lapses quickly or escalates into LT-ASM if the move sustains.Criteria: Short-term (5 / 15 / 30-day) price-volume abnormality — high-low and close-to-close price variation over the window. Adds 100% margin and a 5% (then 2%) price band.Exchange notice · 2026-08-07

Morepen Laboratories Ltd. (MOREPENLAB)

Volume: 1,25,27,070Avg Vol 1W: 2,08,14,890.8Avg Vol 1M: 2,76,50,485.0552W Range:33.05122.55
Key Ratios
Checked 5h ago
Market Cap₹6,420 Cr
Current Price₹116.91
Previous Close₹116.54
High / Low (52w)₹122.55 / ₹33.05
Volume1,25,27,070
Avg Vol (1W)2,08,14,890.8
Avg Vol (1M)2,76,50,485.05
Stock P/E25.86
Book Value₹21.56
Dividend Yield
ROE9.8%
ROA
Revenue (TTM)₹1,830 Cr
Revenue Growth
Profit Margin
Total Debt₹26 Cr
Shares Outstanding
Face Value₹2
EPS (TTM)₹1.85
P/B2.22
Debt / Equity0.06
50 DMA₹77.99
200 DMA₹51.28
Day change+0.32%
SurveillanceLT-ASM · ASM 1 · ST-ASM · ASM 1
Price Chart
116.91 117.83% · 1Y
1193411.9Cr
2025-09-10
2026-09-09

20-day avg volume: 2.8Cr shares

Pros
  • Company is almost debt-free.
Cons
  • Revenue fell 28% YoY.
Quarterly Results
MetricSept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Revenue₹438 Cr₹453 Cr₹466 Cr₹425 Cr₹412 Cr₹484 Cr₹485 Cr₹570 Cr
EBITDA₹47 Cr₹37 Cr₹30 Cr₹20 Cr₹24 Cr₹40 Cr₹27 Cr₹79 Cr
Net Profit₹35 Cr₹27 Cr₹20 Cr₹11 Cr₹41 Cr₹28 Cr₹16 Cr₹56 Cr
EPS
Profit & Loss (Annual)
MetricMar 2025Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Mar 2026Jun 2026
Revenue₹1,830 Cr₹382 Cr₹391 Cr₹370 Cr₹458 Cr₹463 Cr₹1,827 Cr₹541 Cr
EBITDA₹163 Cr₹21 Cr₹15 Cr₹22 Cr₹36 Cr₹32 Cr₹111 Cr₹77 Cr
Net Profit₹118 Cr₹12 Cr₹8 Cr₹14 Cr₹24 Cr₹20 Cr₹95 Cr₹54 Cr
EPS2.21.73
Balance Sheet
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets₹615 Cr₹663 Cr₹858 Cr₹1,070 Cr₹1,110 Cr₹1,293 Cr₹1,778 Cr₹1,936 Cr
Total Liabilities₹363 Cr₹380 Cr₹434 Cr₹492 Cr₹358 Cr₹446 Cr₹591 Cr₹689 Cr
Equity₹253 Cr₹284 Cr₹424 Cr₹578 Cr₹752 Cr₹847 Cr₹1,187 Cr₹1,247 Cr
Total Debt
Cash Flow
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating₹18 Cr₹17 Cr₹52 Cr₹-35 Cr₹-75 Cr₹111 Cr₹69 Cr₹58 Cr
Investing₹-13 Cr₹-12 Cr₹-70 Cr₹-32 Cr₹-47 Cr₹-83 Cr₹-322 Cr₹-123 Cr
Financing₹0 Cr₹5 Cr₹47 Cr₹66 Cr₹144 Cr₹5 Cr₹300 Cr₹97 Cr
Free Cash Flow₹18 Cr₹17 Cr₹52 Cr₹-35 Cr₹-75 Cr₹111 Cr₹69 Cr₹58 Cr
Shareholding
Promoter 35.65% Institutions 2.74% Public 61.6%
Efficiency & Working Capital
ROCE7.6%
Interest Coverage6.7
Dividend Payout
Debtor Days67 d
Inventory Days55 d
Payable Days64 d
Cash Conversion Cycle58 d
Working Capital Days122 d
Shareholding Details

As of 2026-06-30

Promoter35.7%
FII1.5%
DII1.3%
Institutions2.7%
Public61.6%
Promoter Pledge0%
No. of Shareholders4,34,912
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodMar 2024Jun 2024Aug 2024Aug 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Promoters38.2%38.2%35.7%35.7%35.7%35.7%35.7%35.7%35.7%35.7%35.7%35.7%
FIIs1.9%1.7%7.7%7.7%2.1%2.2%1.9%1.7%1.6%1.6%1.6%1.5%
DIIs2.2%2.1%2.9%2.9%1.7%1.6%1.7%1.5%1.5%1.3%1.3%1.3%
Public57.8%58%53.7%53.7%60.6%60.5%60.7%61.1%61.2%61.5%61.5%61.6%
Promoter Pledge0%0%0%0%0%0%0%0%0%0%0%0%
No. of Shareholders3,36,0193,48,7663,52,8393,52,8394,30,9294,48,3614,68,8604,61,1804,61,8534,53,1374,47,2864,34,912
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202503
Major Shareholders (>1%)
NameCategoryStakeShares
Pinfold Overseas LimitedPublic Shareholding7%3.85 Cr
Scope Credits And Financial Services Pvt. Ltd.Shareholding of Promoter and Promoter Group2.8%1.56 Cr
Concept Credits And Consultants Pvt. Ltd.Shareholding of Promoter and Promoter Group2.8%1.53 Cr
Brook Investments And Financial Services Pvt. LtdShareholding of Promoter and Promoter Group2.8%1.52 Cr
Solitary Investments And Financial Services Pvt. Ltd.Shareholding of Promoter and Promoter Group2.8%1.51 Cr
Solace Investments And Financial Services Pvt. Ltd.Shareholding of Promoter and Promoter Group2.8%1.51 Cr
Mid Med Financial Services And Investments Pvt. Ltd.Shareholding of Promoter and Promoter Group2.7%1.50 Cr
React Investments And Financial Services Pvt. Ltd.Shareholding of Promoter and Promoter Group2.7%1.49 Cr
Epitome Holdings Pvt.ltd.Shareholding of Promoter and Promoter Group2.7%1.45 Cr
Seed Securities And Services Pvt. Ltd.Shareholding of Promoter and Promoter Group2.6%1.43 Cr
Square Investments And Financial Services Pvt. Ltd.Shareholding of Promoter and Promoter Group2.6%1.41 Cr
Morepen Laboratories LimitedPublic Shareholding1%55,77,144
Sushil SuriShareholding of Promoter and Promoter Group1%55,01,510
Anju SuriShareholding of Promoter and Promoter Group1%51,86,369
Liquid Holdings Pvt. Ltd.Shareholding of Promoter and Promoter Group0.9%50,03,000
Sonia Pankaj BajajShareholding of Promoter and Promoter Group0.7%36,79,718
Sanjay SuriShareholding of Promoter and Promoter Group0.6%34,17,240
Sunita SuriShareholding of Promoter and Promoter Group0.6%31,92,240
Varun SuriShareholding of Promoter and Promoter Group0.6%30,52,357
Mamta SuriShareholding of Promoter and Promoter Group0.6%30,04,000
Sanjay Suri (sanjay Suri Sons Huf)Shareholding of Promoter and Promoter Group0.4%21,00,000
Shalu SuriShareholding of Promoter and Promoter Group0.4%20,52,250
Anubhav Suri (arun Suri Sons Huf)Shareholding of Promoter and Promoter Group0.3%15,00,000
Sushil Suri (sushil Suri Sons Huf)Shareholding of Promoter and Promoter Group0.2%12,01,560
Gulfy MalhotraShareholding of Promoter and Promoter Group0.2%11,50,000
Board of Directors
NameDesignationYear
Sushil SuriChairman / Executive Director / M D / Promoter2025
Sanjay SuriWTD & Executive Director2025
Praveen Kumar DuttIndependent Non Exe. Director2025
Ranjit KhattarIndependent Non Exe. Director2025
SavitaIndependent Non Exe. Director2025
Sharad JainIndependent Non Exe. Director2025
Vipul Kumar SrivastavaCompany Secretary2025
Segments — Product
SegmentRevenueShare
Pharmaceuticals₹0 Cr
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2025₹2200110110
Corporate Actions
TypeDateValueRemark
forthcoming2026-09-18Dividend
dividend2026-09-18₹0.2 (10%)Final
forthcoming2026-08-04Board Meetings
dividend2025-08-29₹0.2 (10%)Final
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
20251710070195
20251650010172
20256007022
Insider / Designated-Person Trades

11 recent disclosure(s)

Liquid Holdings Private LimitedAcquisition · 50,00,000
React Investments and Financial Services Private LimitedAcquisition · 35,00,000
Mid-Med Financial Services and Investments Private LimitedAcquisition · 35,00,000
Square Investments and Financial Services Private LimitedAcquisition · 35,00,000
Solitary Investments and Financial Services Private LimitedAcquisition · 35,00,000
Solace Investments and Financial Services Private LimitedAcquisition · 35,00,000
Company Information
Incorporated1984
ChairmanSushil Suri
AuditorS P Babuta & Associates
Investor Email[email protected]
🌐 www.morepen.com

📍 Morepen Village, Nalagarh Road Near Baddi, Solan, Himachal Pradesh, 173205

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

More stocks

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search